CGTX
Cognition Therapeutics, Inc. Healthcare Biotechnology
7/12
Innovation Score
Patent Activity
3/3
29 patents found
FUZZY
Cash Runway
1/3
18 months of cash remaining based on current burn rate.
Cash on hand: $31.1M
Cash on hand: $31.1M
Revenue Trajectory
1/3
Revenue: $0.0M
Revenue growth data unavailable.
Revenue growth data unavailable.
Management Quality
2/3
Insider ownership: 8.4%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$100.2M
Revenue
$0.0M
Revenue Growth (YoY)
N/A
Cash on Hand
$31.1M
Cash Runway
18 months
Shares Outstanding
89.5M
Insider Ownership
8.4%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
Patents (29)
Match type: FUZZY — company name matched partially; verify assignee
- Machine-learning based analysis, prediction, and response based on electromagnetic waveforms
- Machine-learning based analysis and response based on electromagnetic waveforms and sensor data
- Execution of a genetic algorithm having variable epoch size with selective execution of a training algorithm
- Pre-processing for data-driven model creation
- Machine-learning based analysis and response to electromagnetic waveforms
7-Step Risk Assessment
How CGTX maps to our micro cap methodology:
- Innovation Signal 29 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 18 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory Revenue data unavailable.
- Management Alignment Insiders hold 8.4% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $100.2M company.
Financial Detail
Free Cash Flow
$-27.8M
FCF Yield
-27.7%
Return on Equity
-92.8%
Debt / Equity
1.6%
Gross Margin
N/A
Profit Margin
N/A
Operating Margin
N/A
Price / Book
3.34
Current Ratio
5.92
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-06-27